Literature DB >> 8577011

How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials.

F Fernández-Banares1, E Cabré, M Esteve-Comas, M A Gassull.   

Abstract

BACKGROUND: The purpose of the study was to evaluate, using meta-analysis techniques, whether enteral nutrition is effective in inducing clinical remission in active Crohn's disease.
METHODS: Randomized trials either comparing enteral nutrition with steroids or comparing elemental (amino acid-based) with nonelemental diets were selected using MEDLINE (1984 to 1994), reference lists from published articles, reviews, and abstracts from major gastrointestinal meetings. Sixteen studies fulfilled the inclusion criteria (four published as abstracts). Crude rates for induction of remission were collected on an intention-to-treat basis by three independent observers. Each study was given a quality score, based on predetermined criteria.
RESULTS: The pooled odds ratio (OR) for all type of enteral diets compared with steroid therapy was 0.35 (95% CI, 0.23 to 0.53). This result was similar for the best studies (by quality score) combined, for trials using tube feeding combined, and when noncompliant patients were withdrawn. Further subgroup analyses were conducted on the basis of the type of diet administered. Peptide-based diets were significantly inferior to steroids (pooled OR, 0.32; CI, 0.20 to 0.52). There was a trend to lower remission rate after elemental diets than after steroids (pooled OR, 0.44; CI 0.17 to 1.12). On the other hand, pooled OR for whole protein-based diets compared with elemental diets was 1.28 (CI, 0.40 to 4.02).
CONCLUSIONS: Data available to date show that steroids are better than enteral nutrition to induce remission in active Crohn's disease. These results are more evident when peptide-based diets are administered, but they are not conclusive when either elemental or whole protein-based diets are used.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8577011     DOI: 10.1177/0148607195019005356

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  32 in total

1.  New treatments for inflammatory bowel disease.

Authors:  David S Rampton; D Phil
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

Review 2.  Therapy of Crohn's disease in childhood.

Authors:  R M Beattie
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

3.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

4.  Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn's disease?

Authors:  A F Rodrigues; T Johnson; P Davies; M S Murphy
Journal:  Arch Dis Child       Date:  2007-05-02       Impact factor: 3.791

Review 5.  Nutritional status and nutritional therapy in inflammatory bowel diseases.

Authors:  Corina Hartman; Rami Eliakim; Raanan Shamir
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

6.  Can nutritional therapy replace pharmacologic therapy in pediatric Crohn's disease?

Authors:  Miquel A Gassull
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-12-23

Review 7.  Nutritional management of Crohn's disease in childhood.

Authors:  R M Beattie
Journal:  J R Soc Med       Date:  1998-03       Impact factor: 5.344

Review 8.  Impact of environmental and dietary factors on the course of inflammatory bowel disease.

Authors:  Eduard Cabré; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 9.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

10.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.